Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634344 · ClinicalTrials.gov registry record · Phase 1
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
A Phase 1 study, sponsored by Dizal Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04634344 is a Phase 1 study that was terminated before completion, run by Dizal Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT04634344, a Phase 1 study, was terminated before completion, sponsored by Dizal Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Interventions
- DRUG DZD2269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634344
The ClinicalTrials.gov registry entry for NCT04634344 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DZD2269 is the first listed.
NCT04634344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04634344 about?
NCT04634344 is a clinical study titled "Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC". This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will a...
What is the current status of trial NCT04634344?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-04-12. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT04634344?
The interventions under investigation include: DZD2269 (DRUG).
Who is sponsoring clinical trial NCT04634344?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.